AG
RLAY icon

Algert Global’s Relay Therapeutics RLAY Stock Holding History

Algert Global’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$483K Sell
48,510
-97,990
-67% -$877K 0.01% 971
2025
Q4 		$1.24M Sell
146,500
-262,340
-64% -$1.87M 0.02% 806
2025
Q3 		$2.13M Sell
408,840
-593,176
-59% -$2.26M 0.04% 668
2025
Q2 		$3.47M Buy
1,002,016
+70,765
+8% +$210K 0.07% 452
2025
Q1 		$2.44M Sell
931,251
-63,672
-6% -$249K 0.06% 537
2024
Q4 		$4.1M Buy
994,923
+481,646
+94% +$2.62M 0.1% 346
2024
Q3 		$3.63M Buy
513,277
+36,389
+8% +$272K 0.1% 359
2024
Q2 		$3.11M Buy
476,888
+174,953
+58% +$1.2M 0.1% 321
2024
Q1 		$2.51M Buy
301,935
+69,794
+30% +$681K 0.1% 341
2023
Q4 		$2.56M Buy
232,141
+31,318
+16% +$264K 0.1% 332
2023
Q3 		$1.69M Buy
200,823
+76,573
+62% +$823K 0.08% 418
2023
Q2 		$1.56M Buy
124,250
+90,039
+263% +$1.12M 0.07% 480
2023
Q1 		$563K Sell
34,211
-41,480
-55% -$744K 0.03% 794
2022
Q4 		$1.13M Buy
+75,691
New +$1.45M 0.06% 521

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Algert Global's RLAY Position: Q1 2026 in Review

Algert Global reduced its Relay Therapeutics (RLAY) stake by 67% in Q1 2026, selling an estimated $877K and leaving 48,510 shares worth $483K. The position accounts for 0.01% of the portfolio, ranked #971.

Algert Global first reported a position in RLAY in Q4 2022 and has held it in 14 quarters since. The position peaked at $4.1M in Q4 2024. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Algert Global held 48,510 shares of Relay Therapeutics worth $483K as of Q1 2026.
  • Algert Global sold 97,990 Relay Therapeutics shares in Q1 2026, an estimated $877K.
  • Relay Therapeutics made up 0.01% of Algert Global's portfolio in Q1 2026, its #971 holding.
  • Algert Global first reported a position in Relay Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Algert Global's Relay Therapeutics position peaked at $4.1M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.